Trials that use: P-values
New to this method? Read the tutorial →
20,601 results
- RuRaLIndependent statistical analysis of Hypocaloric Nutrition in Critically Ill Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01531335).
- Rural Home Hospital: Proof of Concept: Complete Statistical AnalysisIndependent statistical analysis of Rural Home Hospital: Proof of Concept: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04531280).
- Rural NDPPIndependent statistical analysis of The National Diabetes Prevention Program in Rural Communities: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05387434).
- Rutgers Pilot for PREDICT- Patient LAB Test: Complete Statistical AnalysisIndependent statistical analysis of Rutgers Pilot for PREDICT- Patient LAB Test: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05607043).
- Ruxolitinib and Lenalidomide for Patients With Myelofibrosis: Complete Statistical AnalysisIndependent statistical analysis of Ruxolitinib and Lenalidomide for Patients With Myelofibrosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01375140).
- Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (MF): Complete Statistical AnalysisIndependent statistical analysis of Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (MF): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02267278).
- Ruxolitinib for Adult T-Cell Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Ruxolitinib for Adult T-Cell Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01712659).
- Ruxolitinib for Cancer Cachexia: Complete Statistical AnalysisIndependent statistical analysis of Ruxolitinib for Cancer Cachexia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT04906746).
- Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of Ruxolitinib in Combination With Pemetrexed/Cisplatin in Non Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Ruxolitinib in Seborrheic Dermatitis: Complete Statistical AnalysisIndependent statistical analysis of Ruxolitinib in Seborrheic Dermatitis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05787860).
- Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: Complete Statistical AnalysisIndependent statistical analysis of Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: primary endpoint results, effect estimate with confidence interval, sample-size…
- RV001V, a RhoC Anticancer Vaccine, Against Metastasis From Solid Tumours: Complete Statistical AnalysisIndependent statistical analysis of RV001V, a RhoC Anticancer Vaccine, Against Metastasis From Solid Tumours: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03199872).
- RVA FlavorsIndependent statistical analysis of Potential Effects of Electronic Nicotine Delivery System Flavor Regulations on African American Menthol Smokers: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- RVD LiteIndependent statistical analysis of Lenalidomide/Bortezomib/Dexamethasone for Multiple Myeloma (MM): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01782963).
- RVDDIndependent statistical analysis of Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- RVEcIndependent statistical analysis of Booster Dose (50 µg) of Recombinant Ricin Toxin Vaccine (RVEc™) in Previously Vaccinated Healthy Adults: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- RVIIndependent statistical analysis of REVITIVE for the Treatment of Patients With Venous Insufficiency: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02114307).
- RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic Cancer: Complete Statistical AnalysisIndependent statistical analysis of RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- RxPONDERIndependent statistical analysis of the randomized phase 3 RxPONDER trial, including its invasive disease-free survival endpoint, Cox proportional-hazards analyses, menopausal-status interaction, post-hoc distant relapse-free survival results, safety, and statistical interpretation.
- RxSight Light Adjustable Lens and Light Delivery Device New Enrollment Study: Complete Statistical AnalysisIndependent statistical analysis of RxSight Light Adjustable Lens and Light Delivery Device New Enrollment Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- RYR1Independent statistical analysis of Antioxidant Therapy in RYR1-Related Congenital Myopathy: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02362425).
- S-Adenosyl Methionine (SAMe) to Treat Patients With Chronic Hepatitis C: Complete Statistical AnalysisIndependent statistical analysis of S-Adenosyl Methionine (SAMe) to Treat Patients With Chronic Hepatitis C: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00475176).
- S-CASTIndependent statistical analysis of Smoking-Cessation and Stimulant Treatment (S-CAST): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01077024).
- S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma: Complete Statistical AnalysisIndependent statistical analysis of S0008: Chemotherapy Plus Biological Therapy in Treating Patients With Melanoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00006237).
- S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin’s Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of S0016 Combination Chemotherapy With Monoclonal Antibody Therapy in Newly Diagnosed Non-Hodgkin's Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of S0032, Combination Chemotherapy Plus Hormone Therapy in Treating Patients With Metastatic Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- S0232 Dexamethasone With or Without Lenalidomide in Treating Patients With Previously Untreated Stage I, Stage II, or Stage III Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of S0232 Dexamethasone With or Without Lenalidomide in Treating Patients With Previously Untreated Stage I, Stage II, or Stage III Multiple Myeloma: primary endpoint results, effect estimate with confidence…
- S0300, Celecoxib in Preventing Breast Cancer in Premenopausal Women: Complete Statistical AnalysisIndependent statistical analysis of S0300, Celecoxib in Preventing Breast Cancer in Premenopausal Women: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00088972).
- S0307 Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer.: Complete Statistical AnalysisIndependent statistical analysis of S0307 Phase III Trial of Bisphosphonates as Adjuvant Therapy for Primary Breast Cancer.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- S0356 Oxaliplatin, 5-FU, Radiation Therapy (RT), Surgery for Pts With Stage II or III Cancer of Esophagus or Gastroesophageal (GE) Junction: Complete Statistical AnalysisIndependent statistical analysis of S0356 Oxaliplatin, 5-FU, Radiation Therapy (RT), Surgery for Pts With Stage II or III Cancer of Esophagus or Gastroesophageal (GE) Junction: primary endpoint results, effect estimate with confidence…
- S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer: Complete Statistical AnalysisIndependent statistical analysis of S0415 Cetuximab in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- S0433 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Treating Older Patients With Stage II, Stage III, or Stage IV Non-Hodgkin’s Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of S0433 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Treating Older Patients With Stage II, Stage III, or Stage IV Non-Hodgkin's Lymphoma: primary endpoint results, effect estimate…
- S0500 Treatment Decision Making Based on Blood Levels of Tumor Cells for Metastatic Breast Cancer Treated With Chemo: Complete Statistical AnalysisIndependent statistical analysis of S0500 Treatment Decision Making Based on Blood Levels of Tumor Cells for Metastatic Breast Cancer Treated With Chemo: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- S0501 Fludarabine, Melphalan, and Donor Stem Cell Transplant Followed By Tacrolimus and Methotrexate in Treating Patients for Relapsed Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of S0501 Fludarabine, Melphalan, and Donor Stem Cell Transplant Followed By Tacrolimus and Methotrexate in Treating Patients for Relapsed Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size…
- S0635: Erlotinib and Bevacizumab in Stage IIIB and IV Bronchioloalveolar Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of S0635: Erlotinib and Bevacizumab in Stage IIIB and IV Bronchioloalveolar Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of S0800, Nab-Paclitaxel, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer: primary endpoint results, effect estimate with confidence interval,…
- S0802 – Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of S0802 - Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer: primary endpoint results, effect estimate with…
- S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer: Complete Statistical AnalysisIndependent statistical analysis of S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- S1216A detailed statistical analysis of S1216, a randomized phase 3 trial comparing LHRHa plus TAK-700 with LHRHa plus bicalutamide in metastatic prostate cancer, including overall survival, progression-free survival, Cox modeling, hazard ratios,…
- S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib: Complete Statistical AnalysisIndependent statistical analysis of S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib: primary endpoint results, effect estimate with…
- S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis: Complete Statistical AnalysisIndependent statistical analysis of S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- S2SIndependent statistical analysis of Screen to Save: A Colorectal Cancer Educational Intervention: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03907579).
- S8PKIndependent statistical analysis of Safety and Performance of the Steroid-Releasing S8 Sinus Implant: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01894503).
- S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma: Complete Statistical AnalysisIndependent statistical analysis of S9811 Hydroxyurea in Treating Patients With Unresectable Benign Meningioma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00003590).
- SAABIndependent statistical analysis of Corticosteroid Pulse After Ablation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00807586).
- SABRseqIndependent statistical analysis of Sequencing of Stereotactic Ablative Body Radiotherapy in Combination With PD-1 Blockade Using Pembrolizumab in Metastatic Non-Small Cell Lung Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size…
- SACARIndependent statistical analysis of Strategies for Aggressive Central Afterload Reduction in Patients With Heart Failure: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…